Clovis Oncology heralds a PARP victory in frontline ovarian cancer — does anyone really care much?
Early on Thursday, Clovis Oncology trumpeted positive Phase III data for their PARP player Rubraca in frontline maintenance care of ovarian cancer, outlining a much improved PFS rate compared to placebo.
The small-cap stock price $CLVS, which was eviscerated and relegated to Wall Street sideshow long ago, spiked 52%. That raised a cheer from the remaining faithful who have seen the stock tank 95% over the last 5 years, as Clovis has struggled to find its way as the third PARP playing against major league rivals at AstraZeneca — the dominant pioneer — and GSK, which saw their PARP acquisition as a key part of its new oncology strategy.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.